Key result
ACE gene PstI allele homozygosity linked to ~130% greater diabetic nephropathy risk in IDDM.
Why the study?
The relationship between DNA polymorphisms in the ACE gene, serum ACE activity, and the risk of diabetic nephropathy in IDDM patients was unclear.
Do DNA polymorphisms in the ACE gene increase the risk of diabetic nephropathy in Jewish IDDM patients?
Comparison
Homozygous for PstI site allele vs other ACE genotypes
Design
Case-control study
Authors
Loading...
May support genetic risk stratification in IDDM; leaves open replication and clinical utility of ACE PstI polymorphism.
Case-Control (n=166)
Do DNA polymorphisms in the ACE gene increase the risk of diabetic nephropathy in Jewish IDDM patients?
Odds Ratio: 2.3 (95% CI 1.2–4.5)
Genetic variability at the ACE locus, specifically the PstI polymorphism in intron 7, is associated with an increased risk of diabetic nephropathy in IDDM patients.
Manuel Freire (1998) conducted a case-control in insulin-dependent diabetes mellitus (IDDM) (n=166). Homozygosity for the allele with the PstI site in the ACE gene vs. Other genotypes was evaluated on diabetic nephropathy (OR 2.3, 95% CI 1.2-4.5). Homozygosity for the allele with the PstI site in the ACE gene was associated with a 2.3-fold increased risk of diabetic nephropathy (95% CI 1.2-4.5) in IDDM patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: